URGN
UroGen Pharma LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.17B
P/E Ratio
—
EPS
$-3.19
Beta
1.44
52W High
$30.00
52W Low
$3.42
50-Day MA
$20.29
200-Day MA
$20.33
Dividend Yield
—
Profit Margin
-139.80%
Forward P/E
—
PEG Ratio
0.00
About UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) is an innovative biotechnology company specializing in the development of specialized therapies for urological diseases, with a focus on urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel platform, UroGen enables targeted, sustained local drug delivery, thereby optimizing therapeutic efficacy while reducing systemic side effects. With a promising clinical pipeline addressing significant unmet medical needs in urology, UroGen is strategically poised to advance patient care and establish itself as a leader in the urological oncology space.
Fundamentals
| Revenue (TTM) | $109.79M |
| Gross Profit (TTM) | $97.34M |
| EBITDA | $-124.56M |
| Operating Margin | -50.50% |
| Return on Equity | -1481.00% |
| Return on Assets | -32.10% |
| Revenue/Share (TTM) | $2.28 |
| Book Value | $-2.18 |
| Price-to-Book | 19.27 |
| Price-to-Sales (TTM) | 10.70 |
| EV/Revenue | 10.77 |
| EV/EBITDA | -2.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 54.00% |
| Shares Outstanding | $48.68M |
| Float | $38.66M |
| % Insiders | 3.75% |
| % Institutions | 98.39% |
Historical Volatility
HV 10-Day
75.25%
HV 20-Day
71.35%
HV 30-Day
65.61%
HV 60-Day
63.59%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($33.88 target)
1
Strong Buy6
Buy1
HoldData last updated: 4/29/2026